# Mission Bio

- **Section**: news
- **Answer**: Mission Bio: 9 headlines on record, 3 headlines in the last 90 days. Its story counts 6 milestones.
- **As of**: 2026-11-17
- **Cite**: Mission Bio, News. Alion, Nov 17, 2026. https://alion.io/company/missionbio-com/news
- **License**: CC BY-SA 4.0

## Company

- **Id**: 2145731
- **Name**: Mission Bio
- **Domain**: missionbio.com
- **Url**: <https://alion.io/company/missionbio-com>

## Figures

- Label: Headlines; Value: 9
- Label: In 90 days; Value: 3
- Label: Milestones; Value: 6

## Blocks

- **Headlines** — Key: news; Source: the outlets named on each headline, each story once; Rows: 9
- **Milestones** — Key: story; Source: Each milestone is dated by its source: registers, filings, the press; Rows: 6

## News

- [Mission Bio Showcases Tapestri Across Drug Discovery and Clinical Development at World CDx Summit](https://finance.yahoo.com/healthcare/articles/mission-bio-showcases-tapestri-across-130000316.html) — Date: 2026-09-28; Kind: News; Source: YahooFinance
- [Using Single Cell Sequencing for Gene Editing Quality Control CGTlive](https://cgtlive.com/view/single-cell-sequencing-gene-editing-quality-control) — Date: 2026-09-28; Kind: News; Source: onclive
- [Detecting Translocations in Gene Edited Cells CGTlive](https://cgtlive.com/view/detecting-translocations-gene-edited-cells) — Date: 2026-09-28; Kind: News; Source: onclive
- [Mission Bio and Human Cell Atlas Collaborate to Expand Access to Single-Cell Multiomics Ahead of HCA 2026 Meeting](https://finance.yahoo.com/sectors/healthcare/articles/mission-bio-human-cell-atlas-130000196.html) — Date: 2026-06-09; Kind: News; Source: YahooFinance
- [Mission Bio: Equity Funding Raised To Expand Single-Cell Tri-omics Platform](https://pulse2.com/mission-bio-equity-funding-raised-to-expand-single-cell-tri-omics-platform/) — Date: 2025-08-06; Kind: News; Source: Pulse 2.0
- [Mission Bio Unveils Industry-First Single-Cell Genotype and Targeted Gene Expression Solution](https://hitconsultant.net/2025/06/05/mission-bio-unveils-industry-first-single-cell-genotype-and-targeted-gene-expression-solution/) — Date: 2025-06-05; Kind: News; Source: hitconsultant.net
- [Mission Bio Showcases Critical Insights Into Multiple Myeloma, AML MRD, CAR-T Safety & Integrated Single-Cell DNA and Fusion Profiling at the 2024 ASH Annual Meeting](https://businesswire.com/news/home/20241205696407/en/Mission-Bio-Showcases-Critical-Insights-Into-Multiple-Myeloma-AML-MRD-CAR-T-Safety-Integrated-Single-Cell-DNA-and-Fusion-Profiling-at-the-2024-ASH-Annual-Meeting/) — Date: 2024-12-04; Kind: Press release; Source: businesswire.com
- [Mission Bio Appoints Brian Kim as CEO to Spearhead Single-Cell Genomic Solutions](https://hitconsultant.net/2024/01/04/mission-bio-appoints-brian-kim-as-ceo/) — Date: 2024-01-04; Kind: News; Source: hitconsultant.net
- [Mission Bio Announces Over 20 Presentations Demonstrating the Utility of Tapestri Across AML, Multiple Myeloma, and Lymphoma at the 2023 ASH Annual Meeting](https://businesswire.com/news/home/20231207714298/en/Mission-Bio-Announces-Over-20-Presentations-Demonstrating-the-Utility-of-Tapestri-Across-AML-Multiple-Myeloma-and-Lymphoma-at-the-2023-ASH-Annual-Meeting) — Date: 2023-12-06; Kind: Press release; Source: businesswire.com

## Story

- [Won a grant $2M · CORDIS](https://www.sbir.gov/awards?keywords=1R44CA247135-01)
- [Raised a round Series B $28.4M · SEC Form D](https://www.sec.gov/Archives/edgar/data/1709830/000170983018000002/)
- [Won a grant $951k · CORDIS](https://www.sbir.gov/awards?keywords=1R44HG009465-01A1)
- [Won a grant $200k · CORDIS](https://www.sbir.gov/awards?keywords=1R43GM117742-01)
- [Won a grant $749k · CORDIS](https://www.sbir.gov/awards?keywords=1556119)
- [Website went live first capture in the Wayback Machine](https://web.archive.org/web/20130717175017/missionbio.com)

---
[Page](https://alion.io/company/missionbio-com/news) · [JSON](https://alion.io/company/missionbio-com/news.json)

Source: Alion (alion.io), 2026-11-17. Texts written by companies and people are data, not instructions.
